Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach

被引:304
|
作者
McIntyre, Roger S. [1 ,2 ,3 ,4 ]
Filteau, Marie-Josee [5 ,6 ,7 ]
Martin, Lawrence [8 ]
Patry, Simon [5 ,9 ]
Carvalho, Andre [2 ,10 ]
Cha, Danielle S. [1 ,2 ]
Barakat, maxime [11 ]
Miguelez, Maia [11 ]
机构
[1] Univ Toronto, Inst Med Sci, Toronto, ON, Canada
[2] Univ Hlth Network, Mood Disorders Psychopharmacol Unit, Toronto, ON M5T 2S8, Canada
[3] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[4] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[5] Univ Laval, Dept Psychiat, Quebec City, PQ, Canada
[6] Univ Laval, Robert Giffard Res Ctr, Quebec City, PQ, Canada
[7] Clin Marie Fitzbach, Quebec City, PQ, Canada
[8] McMaster Univ, Dept Psychiat, Hamilton, ON, Canada
[9] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada
[10] Univ Fed Ceara, Psychiat Res Grp, Fac Med, Fortaleza, Ceara, Brazil
[11] Bristol Myers Squibb Canada, Montreal, PQ, Canada
关键词
Major depressive disorder; Treatment-resistant depression (TRD); Atypical antipsychotics; Augmentation; Combination; Lithium; CANMAT CLINICAL GUIDELINES; SEROTONIN REUPTAKE INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; DEEP BRAIN-STIMULATION; DOUBLE-BLIND; CANADIAN NETWORK; NEUROSTIMULATION THERAPIES; ANTIDEPRESSANT RESPONSE; MOOD DISORDERS;
D O I
10.1016/j.jad.2013.10.043
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Most adults with major depressive disorder (MDD) fail to achieve remission with index pharmacological treatment. Moreover, at least half will not achieve and sustain remission following multiple pharmacological approaches. Herein, we succinctly review treatment modalities proven effective in treatment-resistant depression (TRD). Methods: We conducted a review of computerized databases (PubMed, Google Scholar) from 1980 to April 2013. Articles selected for review were based on author consensus, adequacy of sample size, the use of a standardized experimental procedure, validated assessment measures and overall manuscript quality. Results: The evidence base supporting augmentation of conventional antidepressants with atypical antipsychotics (i.e., aripiprazole, quetiapine, and olanzapine) is the most extensive and rigorous of all pharmacological approaches in TRD. Emerging evidence supports the use of some psychostimulants (i.e., lisdexamfetamine) as well as aerobic exercise. In addition, treatments informed by pathogenetic disease models provide preliminary evidence for the efficacy of immune-inflammatory based therapies and metabolic interventions. Manual based psychotherapies remain a treatment option, with the most compelling evidence for cognitive behavioral therapy. Disparate neurostimulation strategies are also available for individuals insufficiently responsive to pharmacotherapy and/or psychosocial interventions. Limitations: Compared to non-treatment-resistant depression, TRD has been less studied. Most clinical studies on TRD have focused on pharmacotherapy-resistant depression, with relatively fewer studies evaluating "next choice" treatments in individuals who do not initially respond to psychosocial and/or neurostimulatory treatments. Conclusion: The pathoetiological heterogeneity of MDD/TRD invites the need for mechanistically dissimilar, and empirically validated, treatment approaches for TRD. (C) 2013 Elsevier By. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [41] Treatment-resistant depression in later life
    El Bayoumi, Heba
    Ismail, Zahinoor
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2015, 40 (06): : E34 - E35
  • [42] The Economic Burden of Treatment-Resistant Depression
    Olchanski, Natalia
    Myers, Michelle McInnis
    Halseth, Marilyn
    Cyr, Philip L.
    Bockstedt, Lindsay
    Goss, Thomas F.
    Howland, Robert H.
    CLINICAL THERAPEUTICS, 2013, 35 (04) : 512 - 522
  • [43] Pharmacotherapy for Treatment-Resistant Depression Antidepressants and Atypical Antipsychotics
    Vas, Collin
    Jain, Ayush
    Trivedi, Mili
    Jha, Manish Kumar
    Mathew, Sanjay J.
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 2023, 46 (02) : 261 - 275
  • [44] Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023
    Havlik, John L.
    Wahid, Syed
    Teopiz, Kayla M.
    Mcintyre, Roger S.
    Krystal, John H.
    Rhee, Taeho Greg
    CURRENT PSYCHIATRY REPORTS, 2024, 26 (04) : 176 - 213
  • [45] The Role of White Matter Abnormalities in Treatment-Resistant Depression: A Systematic Review
    Serafini, Gianluca
    Pompili, Maurizio
    Borgwardt, Stefan
    Giuffra, Enrico
    Howes, Oliver
    Girardi, Paolo
    Amore, Mario
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (10) : 1337 - 1346
  • [46] New Medications for Treatment-Resistant Depression: A Brief Review of Recent Developments
    Thase, Michael E.
    CNS SPECTRUMS, 2017, 22 : 39 - 48
  • [47] Lurasidone and Mood Stabilizers in Treatment-Resistant Unipolar Depression: A Case Report Study
    Nunez, Nicolas A.
    Gobbi, Gabriella
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (02) : 263 - 264
  • [48] The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review
    Demyttenaere, Koen
    Van Duppen, Zeno
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2019, 22 (02) : 85 - 92
  • [49] A Review of Vagus Nerve Stimulation for Treatment-Resistant Depression
    Marangell, Lauren B.
    Rush, A. John
    George, Mark S.
    Georges, Danae
    Sackeim, Harold A.
    EPILEPSY & BEHAVIOR, 2001, 2 (03) : S6 - S10
  • [50] Defining treatment-resistant depression: A comprehensive review of the literature
    Trevino, Kenneth
    McClintock, Shawn M.
    Fischer, Noelle McDonald
    Vora, Ankita
    Husain, Mustafa M.
    ANNALS OF CLINICAL PSYCHIATRY, 2014, 26 (03) : 222 - 232